Atlas market file · Equity · United States
Profusa, Inc.PFSA
- Last close
- 0.939
- Change
- -0.21%
- 96-bar range
- 0.861 – 56.25
- As of
- 6 Aug 2026
Profusa, Inc. is a surgical & medical instruments & apparatus issuer listed as PFSA on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
PFSA
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 58 weekly closes (-99.98% over the window).
Source rail: Yahoo Finance chart API (PFSA). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for PFSA. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
PFSA public profile
Surgical & medical instruments & apparatus issuer. Profusa, Inc. is connected to current market context, cited company sources and its retained research file.
Profusa, Inc. trades as PFSA on NASDAQ. Profusa, Inc. (PFSA) has a latest verified close of 0.939, down 0.21%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files PFSA under USA Stocks for browsing.
What changed for Profusa, Inc. today
Profusa, Inc. filed an 8-K on July 27, 2026, outlining its ongoing financial struggles (source: SEC EDGAR, https://www.sec.gov/Archives/edgar/data/1859807/000121390026081560/ea0298832-8k_profusa.htm). The company specialises in long-lasting, injectable biosensors and an intelligent data platform, but its balance sheet tells a different story, with negative equity of $28.2 million and cash reserves of just $375,000 (source: SEC EDGAR, https://data.sec.gov/api/xbrl/companyfacts/CIK0001859807.json).
The company’s latest 10-Q filing for the period ending March 31, 2026, shows a net loss of $3.5 million and an operating loss of $4 million (source: SEC EDGAR, https://data.sec.gov/submissions/CIK0001859807.json). Research and development expenses for the quarter were $1.1 million, while cash used in operating activities amounted to $2.6 million (source: SEC EDGAR, https://www.sec.gov/Archives/edgar/data/1859807/000121390026081560/ea0298832-8k_profusa.htm). The company’s weighted average number of shares outstanding was 1.7 million, with a diluted earnings per share of -$2.05 (source: SEC EDGAR, https://data.sec.gov/api/xbrl/companyfacts/CIK0001859807.json).
Profusa’s financial health is precarious, with liabilities of $29.1 million far exceeding its assets of $862,000 (source: SEC EDGAR, https://www.sec.gov/Archives/edgar/data/1859807/000121390026081560/ea0298832-8k_profusa.htm). The company’s 424B3 filings from July 7, 2026, repeatedly emphasise the potential of its biosensors and data platform, while acknowledging that actual results may differ due to risks and uncertainties (source: SEC EDGAR, https://www.sec.gov/Archives/edgar/data/1859807/000121390026075771/ea029714405-424b3_profusa.htm). This disconnect between the company’s ambitious vision and its financial reality is striking.
The company’s capital structure is strained, with negative equity and a history of cash burn. The latest filings indicate a desperate need for additional funding, which Profusa is attempting to secure through its 424B3 offerings (source: SEC EDGAR, https://www.sec.gov/Archives/edgar/data/1859807/000121390026075765/ea029714401-424b3_profusa.htm). The biosensors may be ‘long-lasting,’ but Profusa’s financial runway is looking increasingly short.
Sources & evidence · 9 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
PFSA technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on PFSA
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep PFSA research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
PFSA FAQ
What is Profusa, Inc. (PFSA)?Profusa, Inc. (PFSA) has a latest verified close of 0.939, down 0.21%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates,...
Profusa, Inc. (PFSA) has a latest verified close of 0.939, down 0.21%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for PFSA?Profusa, Inc. (PFSA) has a latest verified close of 0.939, down 0.21%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and...
Profusa, Inc. (PFSA) has a latest verified close of 0.939, down 0.21%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files PFSA under USA Stocks for browsing.
How often is the PFSA page updated?The PFSA public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The PFSA public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for PFSA?The PFSA file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:PFSA. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The PFSA file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:PFSA. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on PFSA?Yes. The workstation can open PFSA, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open PFSA, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this PFSA page investment advice?No. The PFSA page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The PFSA page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →